Developer docs
API playgroundTry for free, no card

Search company profiles

Sorbent Therapeutics

Full company profile

uuid0009xpa

Namestring
Sorbent Therapeutics
Legal namestring
Solaris Paper Pty Ltd
Websiteurl
sorbent.com
Company typeenum
Private
Founded yearint
1952
Descriptiontext

Sorbent is an Australian consumer tissue and hygiene products brand owned by Solaris Paper Pty Ltd (ABN 41 126 825 769), serving Australian consumers since 1952. The company manufactures and distributes a portfolio of toilet paper (3-ply and 4-ply variants including Value Range, Silky White, Hypo-Allergenic, Double Length, and Super Size), flushable wipes (Silky White, Hypo-Allergenic, Intimate, and Kids variants), and facial tissues (DermaCare dermatologically-tested line plus standard Silky White tissues). Core technology centers on tissue paper manufacturing from sustainably sourced wood pulp derived from Eucalyptus and Acacia plantations with a 6-8 year growth cycle, full PEFC chain-of-custody certification, and flushable wipes engineered to meet the AS/NZS 5328:2022 standard for dispersibility under turbulent flow.

The business operates a dual-channel go-to-market model combining broad retail distribution through Australian supermarket chains, pharmacies, convenience stores, and Amazon marketplace with a direct-to-consumer Shopify storefront at sorbent.com. Pricing is not publicly disclosed and is effectively set by retail partners; the brand monetizes through consumer packaged goods hardware sales across multiple pack sizes and price tiers targeting general consumers, sensitive-skin users, premium/enhanced-care buyers, and parents with young children. Sub-brands include Sorbent DermaCare (dermatologically tested facial tissues), Sorbent Kids (Lenny the Lion-branded wipes for children), and Sorbent Value Range (budget-friendly bulk packs).

Sorbent is privately held with no disclosed parent holding company beyond Solaris Paper Pty Ltd, no venture or private equity backers, and no public listing. A trans-Tasman data processing affiliate relationship with Cottonsoft Ltd in New Zealand is the only disclosed corporate linkage. The company holds no patents or trademarks documented in the available material and has no public awards or recognition listed. Operational signals indicate an actively operating brand with sustained product launches, retail distribution, and consumer-facing digital marketing, but no disclosed financial scale, headcount, or growth metrics.

Short descriptiontext

Sorbent is an Australian consumer tissue brand owned by Solaris Paper Pty Ltd, producing toilet paper, facial tissues, and flushable wipes from PEFC-certified sustainable wood pulp for retail and direct-to-consumer sales across Australia since 1952.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSunnyvale, United States
HQ citystring
Sunnyvale
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
kidney disease therapeutics, polymer drug delivery, fluid retention therapy, cardiorenal therapeutics, nephrology drug development
Industry2 codes
PRIMARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
SECONDARYHLAHAKAK
Renal Care Ancillaries (Anemia Management Devices, Phosphate Binder Support, Nutrition Monitoring)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Miscellaneous Chemical Products2890
Product category
Kidney Disease Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Consumer Tissue Products
TypeHardware Sales
Description

Sorbent generates revenue through the sale of toilet paper, facial tissues, and flushable wipes to consumers via retail distribution (supermarkets, pharmacies, convenience stores) and direct e-commerce. Products are sold in various pack configurations (4-pack to 48-pack) at different price points to serve value-seeking and premium segments.

sorbent.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Sorbent DermaCare
Description

Dermatologically tested facial tissues designed to help reduce risk of skin sensitivity for frequent use.

sorbent.com
+2 more records
Core offering1 text field

Sorbent Therapeutics develops fluid-retaining polymers intended as therapeutics for kidney disease. The company's core product platform consists of proprietary, non-absorbed polymers designed to bind fluid and electrolytes in the gastrointestinal tract for the management of fluid overload in renal and cardiorenal indications.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Sorbent is an Australian consumer tissue and hygiene products company offering a comprehensive portfolio of toilet paper, facial tissues, and flushable wipes. The product lineup includes three main categories: toilet paper products (Value Range, Silky White Standard Length, Hypo-Allergenic, Double Length, and Super Size 4-ply), flushable wipes (Silky White, Hypo-Allergenic, Intimate, and Kids variants), and facial tissues (DermaCare line with Thick & Large, Ultra-Soft, and Hypo-Allergenic options, plus standard Silky White tissues). The company has been serving Australians since 1952, emphasizing sustainability with PEFC-certified materials and zero deforestation policy. Sorbent's products are designed for comfort, skin sensitivity, and environmental responsibility.

Product and service1 record
1Fluid-retaining polymer therapeutics (kidney disease)
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeOthers
Description

New Zealand-based affiliated company under Solaris Paper parent. Customer personal information may be transferred to Cottonsoft for the same purposes described in Sorbent's privacy policy. This is a data processing partnership for cross-border customer data management rather than a product or commercial partnership.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeBroad incumbent
Description

AstraZeneca markets Lokelma (sodium zirconium cyclosilicate) for hyperkalemia, directly competing in Sorbent Therapeutics' core renal indication. As a broad incumbent with deep commercial infrastructure in CKD, it is the most relevant large-pharma competitor in the same disease space.

TypeEmerging player
Description

FibroGen developed roxadustat, an HIF-PH inhibitor for anemia in CKD. The overlap in renal disease therapeutics, particularly for CKD complications, makes it a relevant comparable peer in the broader nephrology development space.

TypeDirect peer
Description

Akebia developed vadadustat, an oral HIF inhibitor for anemia in CKD. As a clinical-to-commercial stage renal-focused biotech, Akebia represents a comparable trajectory and strategic positioning to Sorbent Therapeutics in the nephrology specialty pharma category.

TypeDirect peer
Description

Ardelyx is a nephrology-focused specialty pharma that developed tenapanor for hyperphosphatemia in CKD and IBS-C. Its single-therapeutic-area focus on renal disease and small-molecule approach makes it a close comparable in strategic positioning to Sorbent Therapeutics.

5Relypsa
TypeDirect peer
Description

Relypsa developed patiromer (Veltassa), a non-absorbed polymer for hyperkalemia in CKD patients — the most direct comparable to Sorbent Therapeutics' polymer-based renal therapeutics platform. Relypsa was acquired by Galenica Group in 2016 for approximately $1.53B, validating the commercial potential of polymer-based renal drugs.

6Keryx Biopharmaceuticals
TypeDirect peer
Description

Keryx developed and commercialized ferric citrate (Auryxia) for hyperphosphatemia and iron-deficiency anemia in CKD. As a CKD-focused specialty pharma that progressed from clinical development to commercialization, it represents a comparable end-state benchmark for Sorbent Therapeutics.

TypeBroad incumbent
Description

Otsuka markets tolvaptan (Jinarc) for autosomal dominant polycystic kidney disease (ADPKD), making it a relevant broad incumbent in the renal therapeutics space with a focus on slowing CKD progression — strategically adjacent to Sorbent Therapeutics' kidney disease focus.

8Tricida
TypeDirect peer
Description

Tricida developed veverimer, a non-absorbed polymer designed to treat metabolic acidosis in CKD — directly comparable to Sorbent Therapeutics' non-absorbed polymer approach to renal disease. Its single-asset polymer focus and clinical-stage profile mirror Sorbent's structure.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sorbent Therapeutics

Kidney Disease Therapeuticssorbent.com

Sorbent is an Australian consumer tissue brand owned by Solaris Paper Pty Ltd, producing toilet paper, facial tissues, and flushable wipes from PEFC-certified sustainable wood pulp for retail and direct-to-consumer sales across Australia since 1952.

What Sorbent Therapeutics does

Sorbent is an Australian consumer tissue and hygiene products brand owned by Solaris Paper Pty Ltd (ABN 41 126 825 769), serving Australian consumers since 1952. The company manufactures and distributes a portfolio of toilet paper (3-ply and 4-ply variants including Value Range, Silky White, Hypo-Allergenic, Double Length, and Super Size), flushable wipes (Silky White, Hypo-Allergenic, Intimate, and Kids variants), and facial tissues (DermaCare dermatologically-tested line plus standard Silky White tissues). Core technology centers on tissue paper manufacturing from sustainably sourced wood pulp derived from Eucalyptus and Acacia plantations with a 6-8 year growth cycle, full PEFC chain-of-custody certification, and flushable wipes engineered to meet the AS/NZS 5328:2022 standard for dispersibility under turbulent flow.

The business operates a dual-channel go-to-market model combining broad retail distribution through Australian supermarket chains, pharmacies, convenience stores, and Amazon marketplace with a direct-to-consumer Shopify storefront at sorbent.com. Pricing is not publicly disclosed and is effectively set by retail partners; the brand monetizes through consumer packaged goods hardware sales across multiple pack sizes and price tiers targeting general consumers, sensitive-skin users, premium/enhanced-care buyers, and parents with young children. Sub-brands include Sorbent DermaCare (dermatologically tested facial tissues), Sorbent Kids (Lenny the Lion-branded wipes for children), and Sorbent Value Range (budget-friendly bulk packs).

Sorbent is privately held with no disclosed parent holding company beyond Solaris Paper Pty Ltd, no venture or private equity backers, and no public listing. A trans-Tasman data processing affiliate relationship with Cottonsoft Ltd in New Zealand is the only disclosed corporate linkage. The company holds no patents or trademarks documented in the available material and has no public awards or recognition listed. Operational signals indicate an actively operating brand with sustained product launches, retail distribution, and consumer-facing digital marketing, but no disclosed financial scale, headcount, or growth metrics.

Sorbent Therapeutics firmographics

Firmographics
Name
Sorbent Therapeutics
Legal name
Solaris Paper Pty Ltd
Website
https://sorbent.com
Company type
Private
Founded year
1952
Operating status
Operating
Headcount range
11–50 employees
Short description
Sorbent is an Australian consumer tissue brand owned by Solaris Paper Pty Ltd, producing toilet paper, facial tissues, and flushable wipes from PEFC-certified sustainable wood pulp for retail and direct-to-consumer sales across Australia since 1952.
Ownership category
akta.pro rank

Sorbent Therapeutics industry classification

Industry
Product category
Kidney Disease Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Miscellaneous Chemical Products (2890)
akta.pro industry
PRIMARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
SECONDARYHLAHAKAK
Renal Care Ancillaries (Anemia Management Devices, Phosphate Binder Support, Nutrition Monitoring)

Keywords

  • Kidney disease therapeutics
  • Polymer drug delivery
  • Fluid retention therapy
  • Cardiorenal therapeutics
  • Nephrology drug development

Where Sorbent Therapeutics is headquartered

Location

Headquarters

HQ city
Sunnyvale
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Sorbent Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Consumer Tissue Products: Sorbent generates revenue through the sale of toilet paper, facial tissues, and flushable wipes to consumers via retail distribution (supermarkets, pharmacies, convenience stores) and direct e-commerce. Products are sold in various pack configurations (4-pack to 48-pack) at different price points to serve value-seeking and premium segments.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Sorbent Therapeutics product offering

Product offering

Core offering

Sorbent Therapeutics develops fluid-retaining polymers intended as therapeutics for kidney disease. The company's core product platform consists of proprietary, non-absorbed polymers designed to bind fluid and electrolytes in the gastrointestinal tract for the management of fluid overload in renal and cardiorenal indications.

Product overview

Sorbent is an Australian consumer tissue and hygiene products company offering a comprehensive portfolio of toilet paper, facial tissues, and flushable wipes. The product lineup includes three main categories: toilet paper products (Value Range, Silky White Standard Length, Hypo-Allergenic, Double Length, and Super Size 4-ply), flushable wipes (Silky White, Hypo-Allergenic, Intimate, and Kids variants), and facial tissues (DermaCare line with Thick & Large, Ultra-Soft, and Hypo-Allergenic options, plus standard Silky White tissues). The company has been serving Australians since 1952, emphasizing sustainability with PEFC-certified materials and zero deforestation policy. Sorbent's products are designed for comfort, skin sensitivity, and environmental responsibility.

Differentiator

Problem solved

Functional benefit

Brands

  • Sorbent DermaCare: Dermatologically tested facial tissues designed to help reduce risk of skin sensitivity for frequent use.
  • Sorbent Kids
  • Sorbent Value Range

Products and services

  • Fluid-retaining polymer therapeutics (kidney disease)

Companies that use Sorbent Therapeutics

Customer profile

Segments4 records

Ideal customer profiles2 records

Sorbent Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Sorbent Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Cottonsoft LtdminorOthersNew Zealand-based affiliated company under Solaris Paper parent. Customer personal information may be transferred to Cottonsoft for the same purposes described in Sorbent's privacy policy. This is a data processing partnership for cross-border customer data management rather than a product or commercial partnership.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Sorbent Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • AstraZeneca: AstraZeneca markets Lokelma (sodium zirconium cyclosilicate) for hyperkalemia, directly competing in Sorbent Therapeutics' core renal indication. As a broad incumbent with deep commercial infrastructure in CKD, it is the most relevant large-pharma competitor in the same disease space.
  • Otsuka Pharmaceutical: Otsuka markets tolvaptan (Jinarc) for autosomal dominant polycystic kidney disease (ADPKD), making it a relevant broad incumbent in the renal therapeutics space with a focus on slowing CKD progression — strategically adjacent to Sorbent Therapeutics' kidney disease focus.

Emerging players

  • FibroGen: FibroGen developed roxadustat, an HIF-PH inhibitor for anemia in CKD. The overlap in renal disease therapeutics, particularly for CKD complications, makes it a relevant comparable peer in the broader nephrology development space.

Direct peers

  • Akebia Therapeutics: Akebia developed vadadustat, an oral HIF inhibitor for anemia in CKD. As a clinical-to-commercial stage renal-focused biotech, Akebia represents a comparable trajectory and strategic positioning to Sorbent Therapeutics in the nephrology specialty pharma category.
  • Ardelyx: Ardelyx is a nephrology-focused specialty pharma that developed tenapanor for hyperphosphatemia in CKD and IBS-C. Its single-therapeutic-area focus on renal disease and small-molecule approach makes it a close comparable in strategic positioning to Sorbent Therapeutics.
  • Relypsa: Relypsa developed patiromer (Veltassa), a non-absorbed polymer for hyperkalemia in CKD patients — the most direct comparable to Sorbent Therapeutics' polymer-based renal therapeutics platform. Relypsa was acquired by Galenica Group in 2016 for approximately $1.53B, validating the commercial potential of polymer-based renal drugs.
  • Keryx Biopharmaceuticals: Keryx developed and commercialized ferric citrate (Auryxia) for hyperphosphatemia and iron-deficiency anemia in CKD. As a CKD-focused specialty pharma that progressed from clinical development to commercialization, it represents a comparable end-state benchmark for Sorbent Therapeutics.
  • Tricida: Tricida developed veverimer, a non-absorbed polymer designed to treat metabolic acidosis in CKD — directly comparable to Sorbent Therapeutics' non-absorbed polymer approach to renal disease. Its single-asset polymer focus and clinical-stage profile mirror Sorbent's structure.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Sorbent Therapeutics social profiles

Digital presence

Sorbent Therapeutics compliance and trust

Trust signal

Compliance5 records

Sorbent Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sorbent Therapeutics leadership team

Management profile

Number of profiles

Profiles3 records

Sorbent Therapeutics funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sorbent Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sorbent Therapeutics

What does Sorbent Therapeutics do?

Sorbent Therapeutics develops fluid-retaining polymers intended as therapeutics for kidney disease. The company's core product platform consists of proprietary, non-absorbed polymers designed to bind fluid and electrolytes in the gastrointestinal tract for the management of fluid overload in renal and cardiorenal indications.

Is Sorbent Therapeutics a public or private company?

Sorbent Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Sorbent Therapeutics founded?

Sorbent Therapeutics was founded in 1952. It employs 11 to 50 people.

Where is Sorbent Therapeutics based?

Sorbent Therapeutics is headquartered in Sunnyvale, United States, in the North America region.

How does Sorbent Therapeutics make money?

One revenue line is on record: consumer Tissue Products.

Who are Sorbent Therapeutics's main competitors?

Broad incumbents on record are AstraZeneca and Otsuka Pharmaceutical. FibroGen is listed as an emerging player. Direct peers are Akebia Therapeutics, Ardelyx, Relypsa, Keryx Biopharmaceuticals and Tricida.

Does Sorbent Therapeutics have an API?

No public API is recorded for Sorbent Therapeutics.

What industry is Sorbent Therapeutics in?

Sorbent Therapeutics's product category is Kidney Disease Therapeutics. Its primary akta.pro industry code is HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals, with a secondary code of HLAHAKAK, Renal Care Ancillaries (Anemia Management Devices, Phosphate Binder Support, Nutrition Monitoring). Its NAICS code is 325412 and its SIC code is 2890.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals